r-Lung-SARS-CoV-2 model
A human 3D airway screening platform to identify agents with antiviral activity.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
A human 3D airway screening platform to identify agents with antiviral activity.
This platform is based on zPREDICTA’s tissue reconstruction technology that incorporates the tissue-specific extracellular matrix (ECM) and cellular components to replicate the tissue architecture and its biology outside the human body.
Characteristics of zPREDICTA’s r-Lung-SARS-CoV-2 model:
- Air-liquid interphase (ALI): mimics human airway architecture
- r-Lung ECM: ECM reconstructing the microenvironment of the human alveolar space
- Interstitial ECM: ECM reconstructing the microenvironment of the interstitial space
- Ciliated epithelium: airway cells connected by tight junctions into an epithelial sheet with cilia formed on the apical surface (facing the air compartment); once formed, these ciliated epithelial cells express human ACE2 receptors
- Interstitial fibroblasts: stromal fibroblasts found in the interstitial space
- Inflammatory/immune compartment: immune cells capable of mounting an inflammatory response
3D airway tissue model to evaluate agents against SARS-CoV-2
With the rapid spread of SARS-CoV-2, the virus responsible for COVID-19, it is imperative to rapidly deploy therapeutic agents to stop the viral propagation. This application note from zPREDICTA displays the features of its r-Lung-COVID model, a 3D airway tissue model, to identify agents with antiviral activity.
